Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy

David B.K. Golden, Deborah A. Meyers, Anne Kagey-Sobotka, Martin D. Valentine, Lawrence M. Lichtenstein

Research output: Contribution to journalArticlepeer-review

Abstract

Parameters associated with successful venom immunotherapy in insect allergy were sought by comparison of treatment failures with successes. Half-dose treatment was completely protective in 32 patients (successes) but was only partially effective in eight (failures). The outcome of treatment was not related to the severity of pretreatment sting reactions, to the degree of skin-test sensitivity, to an atopic personal history, or to age or gender. The mean yellow jacket venom-specific IgG antibody level (by the Staph-A solid-phase radioimmunoassay) was significantly less in the failures (3.9 ± 0.6 μg/ml) than in the successes (7.3 ± 1.1 μg/ml) (p < 0.01). When the failures were successfully treated, their mean IgG level (6.1 ± 1.3 μg/ml) was significantly greater than that associated with treatment failure (p < 0.025). Patients with an IgG antibody level above 5.0 μg/ml were significantly more likely to be fully protected (p < 0.02). Those whose IgG levels were less than 5 μg/ml had a risk of reaction similar to that in untreated patients. We conclude that early in the maintenance phase of low-dose venom immunotherapy, the risk of a reaction to a challenge sting is significantly greater for those patients with low levels of venom-specific IgG antibodies.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalThe Journal of allergy and clinical immunology
Volume69
Issue number6
DOIs
StatePublished - Jun 1982

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy'. Together they form a unique fingerprint.

Cite this